Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 14/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | BCR | P11274 | 3/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5469673 | 0.93 | EGFR (0.57) | EGFR | |
| SCHEMBL5465042 | 0.91 | MEN1 (0.50) | MEN1KMT2AEGFRABL1BCR | |
| SCHEMBL5463621 | 0.90 | EGFR (0.56) | EGFR | |
| SCHEMBL5456071 | 0.88 | MEN1 (0.49) | MEN1KMT2AEGFRABL1BCR | |
| SCHEMBL5465063 | 0.88 | ABL1 (0.51) | EGFRABL1BCR | |
| SCHEMBL5464195 | 0.88 | MEN1 (0.52) | MEN1KMT2AEGFR | |
| SCHEMBL5465274 | 0.88 | EGFR (0.55) | EGFR | |
| SCHEMBL5461135 | 0.85 | EGFR (0.54) | EGFR | |
| SCHEMBL5461150 | 0.84 | MKNK1 (0.44) | MEN1KMT2AEGFRABL1BCR | |
| SCHEMBL5330700 | 0.84 | EGFR (0.45) | MEN1KMT2AEGFRABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | MEN1 4261/4885KMT2A 4292/4885EGFR 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.